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Islet transplantation is a promising method for the treatment of type 1 diabetes 
mellitus (DM) and has been widely performed around the world. The long-term 
cryopreservation of islets shows many advantages in the field of islet transplantation. 
Previous studies have described the development of novel sheet-type polyvinyl alcohol 
(PVA) macro-encapsulated islets (MEIs) to treat type 1 DM without any immunotherapy. 
The present study examined their beneficial effects on islet cryopreservation. PVA MEIs 
of Wistar rats were divided into three groups of 1-day, 7-day and 30-day 
cryopreservation at -80℃. The 30-day group showed a lower recovery rate of the islet 
number and impaired insulin release in comparison to the 1-day group, whereas no 
significant differences of the in vitro results were observed between the 1-day and 7-day 
groups. The MEIs transplantation recipient mice in the 1-day and 7-day groups reached 
normoglycemia for a 4-week observation period, and the recipients in 30-day group also 
showed a significant decrease followed by a slightly higher non-fasting blood glucose 
level. These results suggest that the novel PVA MEIs are useful for islet long-term 
cryopreservation, and that the use of cryopreserved PVA MEIs may therefore be a 
promising modality for performing DM therapy.  
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1. Introduction  
  Islet transplantation is a promising method for the treatment of type 1 diabetes 
mellitus (DM) [1]. Clinical islet transplantation is still suffering from several major 
obstacles, including insufficient donors, the side effects of immuno-suppressive drugs 
and islet loss in the early stage after transplantation [2-3]. Encapsulated islets (islets 
enclosed in a semi-permeable membrane) emerged in transplantation studies to 
overcome these problems. The transplanted islets can survive in the host immune 
system and can be protected from inflammatory factors that induce cell loss in the early 
stage after transplantation because the semi-permeable membrane can prevent 
high-weight molecules and immune cells to contact with islets, thereby allowing low- 
weight molecules, such as oxygen, glucose, and insulin etc., to freely pass through it.  
   Recently, due to remarkable advances in both research and surgical techniques, islet 
transplantation is now widely performed around the world [1, 4-6]. Cryopreservation 
shows many advantages for research and clinical islet transplantation: 1. Isolated islets 
can be shipped to other institutions worldwide. 2. Islets isolated at different time can be 
accumulated to obtain a sufficient number for transplantation.3. Cryopreservation 
provides the time for quality control of islets before transplantation [7]. Previous studies 



































































macro-encapsulated islets (MEIs) by 1-day freezing and succeed in confirming their 
positive effects on xeno-transplantation [8], allo-transplantation (manuscript in press) 
and prevention of diabetic nephropathy [9-10]. 
  This study tested 2 periods (7 days and 30 days) of freezing and examined their 
functions in vitro and in vivo in comparison to the original method of cryopreservation 
(1-day freezing). The results showed that PVA MEIs in the 7-day cryopreservation 
group could maintain their normal functions in vitro and normalize non-fasting blood 
glucose (NFBG) of diabetic mice in vivo. 
 
2. Materials and Methods 
2.1. Materials  
Polyvinyl alcohol (PVA, molecular weight: 387200, saponification degree: 99.8 
mol %) powder was a generous gift from Prof. Suong-Hyu Hyon (Kyoto University). 
Dimethyl sulfoxide (DMSO) was purchased from Wako Pure Chemical (Osaka, Japan). 
Cell Banker was purchased from Nippon Zenyaku Kogyo (Fukushima, Japan). Type XI 
collagenase was purchased from Sigma-Aldrich (St. Louis, MO, USA). Dextran power 
was purchased from Sigma-Aldrich (Sweden). BSA was purchased from Nacalai 


































































Louis, MO, USA). Rats and mice were purchased from Shimizu Laboratory Supplies Co. 
Ltd. (Kyoto, Japan). The approval to conduct this experiment was obtained from the 
Animal Care Committee of Institute for Frontier Medical Sciences, Kyoto University, 
and the animals were treated according to the experimental protocols under its 
regulations. 
 
2.2 Islets isolation  
  Ten-week old male Wistar rat islets were isolated as described previously [8]. Briefly, 
the rat pancreas was digested by type XI collagenase and then the islets were separated 
by a dextran gradient. The separated islets were thereafter purified by handpicking and 
then were cultured in an RPMI-1640 medium with 10% heat-inactivated fetal bovine 
serum (FBS) and a 1% antibiotics solution overnight.  
 
2.3. Preparation of PVA MEIs  
  The 3% (w/v) PVA solution contained 10% 10 times concentrated Euro-Collins 
(EC) electrolyte solution, 10% heat-inactivated FBS, 5% DMSO and 1% antibiotics in 
dd-water as described previously [8]. Rat islets were pretreated with Cell Banker and 


































































1mm thick polyethylene terephthalate mesh for reinforcement. After this molding 
process, the MEIs were frozen in a computer-controlled program freezer (TAIYO 
Nippon Sanso Corporation, Tokyo, Japan). The cooling rate was set to -3ºC/min until 
the surface temperature of the MEIs reached -10ºC, then changed to -1ºC /min until the 
surface temperature of the MEIs reached -30ºC. 
Thereafter, MEIs were randomly divided into 3 groups, 1-day group (original 
method: 1-day cryopreservation), 7-day group (7-day cryopreservation) and 30-day 
group (30-day cryopreservation). The MEIs were then immediately moved to an -80ºC 
ultra low freezer (SANYO Electric, Tokyo, Japan) and stored for 1, 7 or 30 days to form 
crystallized gels. These gels were thawed rapidly in 37ºC RPMI-1640 medium for a few 
seconds followed by immersion in 4ºC University of Wisconsin (UW) solutions for 24h. 
Finally, after an overnight culture in RPMI-1640 (37ºC, 5%CO2 95% air), the MEIs 
were used in this experiment. 
 
2.4. Morphological changes and islet recovery rate of MEIs after freezing-thawing 
   The morphological changes of MEIs were observed by microscopy and the islet 
numbers were counted to calculate their recovery rate. The islet recovery rate was 




































































2.5. Static incubation 
   Static incubation was performed in the three MEIs groups. MEIs were pre-incubated 
in RPMI-1640 culture medium containing 3.3mm glucose and 0.1% BSA for 1h, and 
then were incubated in RPMI-1640 medium containing 3.3mm glucose for another 1h. 
Thereafter, they were incubated in RPMI-1640 medium containing 16.7mm glucose for 
1 h (glucose stimulation). At last, the MEIs were incubated again in RPMI-1640 
medium containing 3.3mm glucose for 1 h. At the end of each incubation period, the 
medium were collected and frozen for an insulin assay using a rat insulin ELISA kit 
(Shibayagi, Gunma, Japan). The stimulation index (SI) was calculated by the ratio of 
the insulin content in high glucose medium to the insulin content in the first low glucose 
medium. 
 
2.6. MEIs transplantation 
   A type 1 DM animal model was induced in 8-week old male C57BL/6 mice by a 
single injection of STZ (190mg/kg body weight, i.p.) 7 days before transplantation. 


































































hundred encapsulated Wistar rat islets (MEIs size: 20x 15x 1mm) were transplanted into 
the peritoneal cavity of C57BL/6 mice (n=6). NFBG and then the body weights were 
observed until 4 weeks after transplantation. 
 
2.7. Intraperitoneal glucose tolerance test (IPGTT) 
   IPGTT was performed 2 weeks after transplantation. Briefly, after an overnight fast, 
20% glucose solution (2g/kg) was injected into the peritoneal cavity of recipient mice. 
The blood glucose level was then measured at 0, 15, 30, 45, 60, 80, 100 and 120 min 
after injection of the glucose solution. 
 
2.8. Serum insulin and C-peptide contents    
  Blood samples were collected from the sacrificed mice 4 weeks after transplantation. 
After centrifugation, serum samples were frozen for later measurement. The serum 
insulin level was measured using a rat insulin ELISA kit (Shibayagi, Gunma, Japan) and 
the serum C-peptide level was measured using a rat C -peptide ELISA kit (Shibayagi, 
Gunma, Japan). 
 


































































   Transplanted MEIs and recipients’ pancreas were retrieved from mice sacrificed 4 
weeks after transplantation. The samples were fixed in 4% paraformaldehyde solution 
for 24 h, followed by immersion in 70% ethanol at 4℃ for 24~48h. Next, the samples 
were embedded in paraffin and 5 μm thick sequential sections were cut.  
The pancreas sections were stained for H&E and MEIs were stained for insulin as 
described previously [11]. Briefly, glass slides were mounted with 1% rabbit normal 
serum in PBS for 30 min. Subsequently, primary antibody (anti-Insulin guinea pig 
polyclonal antibody) was applied overnight at 4℃. Thereafter, they were incubated with 
peroxidase conjugated rabbit anti-guinea pig immunoglobulins (second antibody) 
diluted to 1:100 in PBS for 30 min. After washing in PBS, coloring reaction was carried 
out. 
 
2. 10. Statistical Analysis  
All results were expressed as the mean ± SEM. Significant differences between the 
groups were tested by an analysis of variance (ANOVA). Statistical significance was 
defined as p<0.05. 
 
 



































































3.1 .Morphological changes and islet recovery rate 
   The MEIs in the three groups showed a normal morphology after freezing-thawing, 
without islet fragments, and no obvious differences were observed between the three 
groups (Fig. 1). The islet recovery rate in the 1-, 7- and 30-day groups were 74.4±
1.72%, 69.6±3.97% and 62.8±3.2%, respectively (7-day vs. 1-day: p>0.05; 30-day vs. 
1-day: p<0.05; Fig. 2).  
 
3.2. Static incubation 
   Static incubation was performed in the three groups to assess the function of the 
PVA MEIs, after freezing-thawing. The MEIs in the three groups showed good insulin 
secretion abilities in response to high glucose concentration (Fig. 3 A). The SI in the 1-, 
7- and 30-day groups was 1.84±0.07, 1.71±0.1 and 1.66±0.07, respectively. No 
significant differences were found between three groups (Fig. 3B). However, the insulin 
release in the basal (3.3 mM) and stimulation (16.7 mM) medium of the 30-day group 
was lower than 1-day group (p<0.05; Fig. 3C). 
 
3.3. MEIs xeno-transplantation 


































































levels in comparison with those in DM group after PVA MEIs xeno-transplantation. 
Moreover, mice in the 1- and 7-day groups achieved normoglycemia (NFBG<200mg/dl) 
within 1 week after transplantation, and maintained normoglycemia for 4 weeks. 
Although mice in the 30-day group did not achieve normoglycemia, the NFBG 
significantly decreased from 485.8±25.1mg/ml to 246.3±19.6mg/dl (at the 4th week) 
after transplantation (Fig. 4A).The MEIs groups maintained their body weight for 4 
weeks. In contrast, the DM group showed a significant decrease in body weight in a 
time-dependent manner (Fig. 4B). 
 
3.4. IPGTT 
  IPGTT was performed 2 weeks after transplantation. The blood glucose changes are 
shown in Figure 5A. The 30-day group and DM group showed significantly higher area 
under the curve (AUC), and the normal group showed a significantly lower AUC in 
comparison to the 1-day group. No significant difference was observed in the AUC 
between the 1-day and 7-day groups. Moreover, the AUC in 30-day group was lower 
than that in DM group (p<0.05; Fig. 5B). 
 


































































    The 1-, 7- and 30-day groups showed higher serum insulin (Fig. 6A) and C 
-peptide (Fig. 6B) concentrations than the DM group (p<0.05), and no significant 
differences were observed among the 1-, 7- and 30-day groups. The normal mouse 
group was omitted in this assessment because of the species cross reaction between the 
rat and mouse in the insulin and C-peptide level.  
 
3.6. Histological findings 
  HE staining of the pancreas of recipient mice was performed in each group to check 
the regeneration of islets in STZ-induced diabetic mice. No intact islets were observed 
in the STZ-induced diabetic mice (DM, 1-, 7- and 30-day groups). In contrast, large 
islets with intact morphology were found in the normal group (Fig. 7A). These results 
indicated that the regeneration of islet did not happen in the STZ-induced diabetic mice. 
   Insulin staining was performed in the MEIs group (1-, 7- and 30-day groups) to 
confirm the surviving islets in the PVA MEIs 4 weeks after transplantation. The islets in 
each MEIs group were positive for insulin staining (Fig. 7B). This result, together with 
results of the serum insulin and C-peptide, indicated that MEIs still survived with a 
normal insulin secretion function 4 weeks after transplantation.  


































































  Encapsulated islets can be divided into two categories: namely, micro-encapsulated 
islets and macro-encapsulated islets. Both types have been emerged and each has their 
own advantages [12-14]. Micro-encapsulated islets are one or a few islets enclosed in 
semi-permeable membranes, which can provide a beneficial surface for diffusion, thus 
maintaining the functions of islets inside. However, they are irretrievable after 
transplantation [15]. In contrast, macro-encapsulated islets are retrievable so that the 
functions of islets inside can be evaluated at anytime; that is the reason why the 
macro-encapsulated islets were employed for transplantation.  
  In previous studies, islets were pretreated with Cell Banker, and 5% DMSO and 10% 
EC solution were used as cryoprotective agents to reduce cryo-damage. Rajotte et al. 
suggested that slow cooling and rapid thawing could protect islets better during 
cryopreservation [16]. Therefore, MEIs were frozen with a slower cooling rate (4ºC ~ 
-10ºC: -3ºC/min; -10ºC ~ -30ºC: -1ºC /min) by a computer-controlled program freezer 
to maintain the islets functions during long-term cryopreservation.  
  The MEIs in all three groups showed good insulin secretion ability in response to 
glucose concentration changes (Fig. 3A) without significant difference in SI (Fig. 3B), 
indicating that MEIs in three groups maintained comparable insulin secretion function. 


































































the 30-day group was lower than the 1-day group. Considering the results of the islet 
recovery rate (Fig 2), it is assumed that the difference in the number of surviving islets 
after cryopreservation resulted in different insulin release in vitro (Fig. 3C) and 
different results in vivo (Figs. 4 and 5). 
   Although MEIs in the 30-day group showed a slightly worse function in vitro in 
comparison to that seen in the 1-day group, and the recipient mice in the 30-day group 
did not achieve normoglycemia, there were still some therapeutic benefits with 30-day 
cryopreserved PVA MEIs in comparison to the DM group in vivo (Figs. 4 and 5). In fact, 
the survival rate of recipients 4 weeks after transplantation was 100% in the 30-day 
group and 17% in the DM group. The results of the NFBG (Fig. 4A), body weight (Fig. 
4B) and IPGTT (Fig. 5) in the 30-day group also showed apparent improvements from 
the DM group. In addition, the MEIs in the 7-day group showed similar results to the 
1-day group in vitro and in vivo. These results indicated that the immediate use of PVA 
MEIs after 1 day freezing is not mandatory, furthermore, 7 days is sufficient for islet 
accumulation for transplantation, islet shipping worldwide and an evaluation of islet 
quality before transplantation. These results lead us to conclude the use of PVA MEIs 
therefore appears to be an effective modality which can be used for clinical islet 



































































  Long- term cryopreserved PVA MEIs showed similar effects to the original PVA 
MEIs (1-day group) both in vitro and in vivo. These results suggest that the PVA MEIs 
have advantages over other MEIs which may therefore make it possible to overcome the 
obstacles of insufficient donors and the side effects of immuno-suppressive drugs, 
because the encapsulation process with cryopreservation technique allows islet 
accumulation, as well as the shipping and quality control in the field of islet 
transplantation. Therefore, the use of PVA MEIs appears to be an effective modality for 
improving clinical DM therapy.   
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Figure Captions: 
Figure 1: Microscope images of PVA MEIs in the 1-day (left), 7-day (middle) and 30-day (right) groups after 
thawing. 
Figure 2: Recovery rate of MEIs after thawing (* p<0.05; vs. 1-day group). 
Figure 3: Insulin secretion test. (A) MEIs in all three groups showed good insulin secretion abilitiy in 
response to glucose concentration changes (* p<0.05). (B) No significant differences of SI were found 
between the three groups. (C) MEIs in 30-day group showed lower insulin release in comparison to those in 
the 1-day group (* p<0.05; vs. 1-day group). 
Figure 4: After MEIs transplantation, the NFBG (A) and body weight (B) changes of recipient mice (n=6). 
Figure 5: IPGTT was performed 2 weeks after MEIs transplantation (DM group: n=5; other groups: n=6). (A) 
Blood glucose changes of the recipient mice. (B) AUC (* p<0.05; vs. 1-day group). 
Figure 6: Serum insulin (A) and C-peptide (B) levels. No significant differences were found among 1-, 7- 
and 30-day groups (n=3). In this evaluation experiment, at 4 weeks after transplantation, only one recipient 
mouse survived (n=1) in DM group, and because of the species cross reaction between rat and mouse in 
rat insulin and C-peptide, the normal mouse group was omitted.  
Figure 7: Histological assessments 4 weeks after transplantation. (A) H&E staining of recipients’ pancreas 
(arrow: islets). (B) Insulin staining of MEIs in 1-day, 7-day and 30-day groups (arrow: islets). 
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